Agilent Technologies, Inc. (A)
| Previous Close | 138.69 |
| Open | 139.23 |
| Bid | 137.56 x 1000 |
| Ask | 137.80 x 900 |
| Day's Range | 136.71 - 139.88 |
| 52 Week Range | 96.80 - 151.58 |
| Volume | |
| Avg. Volume | 1,591,968 |
| Market Cap | 40.348B |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | 33.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.94 (0.68%) |
| Ex-Dividend Date | Apr 01, 2024 |
| 1y Target Est | N/A |
- Business Wire
Padraig McDonnell Assumes Agilent CEO Role
SANTA CLARA, Calif., May 01, 2024--Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31.
- Business Wire
Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution
SANTA CLARA, Calif., May 01, 2024--Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development.
- Business Wire
Agilent Names Simon May to Lead Diagnostics and Genomics Group
SANTA CLARA, Calif., April 29, 2024--Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6.
